ATE415632T1 - Verfahren zur diagnose und behandlung von morbus crohn - Google Patents

Verfahren zur diagnose und behandlung von morbus crohn

Info

Publication number
ATE415632T1
ATE415632T1 AT05809109T AT05809109T ATE415632T1 AT E415632 T1 ATE415632 T1 AT E415632T1 AT 05809109 T AT05809109 T AT 05809109T AT 05809109 T AT05809109 T AT 05809109T AT E415632 T1 ATE415632 T1 AT E415632T1
Authority
AT
Austria
Prior art keywords
disease
crohn
treatment
diagnosis
relates
Prior art date
Application number
AT05809109T
Other languages
English (en)
Inventor
Nicolas Barnich
Arlette Darfeuille-Michaud
Anne-Lise Glasser
Original Assignee
Univ Clermont Auvergne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Clermont Auvergne filed Critical Univ Clermont Auvergne
Application granted granted Critical
Publication of ATE415632T1 publication Critical patent/ATE415632T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05809109T 2004-10-14 2005-10-13 Verfahren zur diagnose und behandlung von morbus crohn ATE415632T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0410865A FR2876798A1 (fr) 2004-10-14 2004-10-14 Diagnostic et traitement de la maladie de crohn

Publications (1)

Publication Number Publication Date
ATE415632T1 true ATE415632T1 (de) 2008-12-15

Family

ID=34951162

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05809109T ATE415632T1 (de) 2004-10-14 2005-10-13 Verfahren zur diagnose und behandlung von morbus crohn

Country Status (10)

Country Link
US (2) US9176131B2 (de)
EP (1) EP1800134B1 (de)
JP (1) JP4896883B2 (de)
AT (1) ATE415632T1 (de)
CA (1) CA2582228C (de)
DE (1) DE602005011316D1 (de)
DK (1) DK1800134T3 (de)
ES (1) ES2317327T3 (de)
FR (1) FR2876798A1 (de)
WO (1) WO2006040481A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2377883A1 (de) * 2010-04-15 2011-10-19 Universite d'Auvergne Clermont I Antagonisten zur Vorbeugung oder Behandlung von entzündlicher Darmerkrankung, speziell von Morbus Crohn
EP2672820B1 (de) 2011-02-07 2019-04-17 The Washington University Mannosidverbindungen und anwendungsverfahren dafür
EP3388441A1 (de) 2012-12-18 2018-10-17 Vertex Pharmaceuticals Incorporated Mannosederivate zur behandlung bakterieller infektionen
MX2015012472A (es) 2013-03-12 2016-02-10 Vertex Pharma Derivados de manosa para el tratamiento de infecciones bacterianas.
CN105682665A (zh) * 2013-05-30 2016-06-15 华盛顿大学 用于治疗细菌性感染的化合物和方法
CN104459154B (zh) * 2014-12-09 2016-04-27 临沂大学 一种新型人工模拟酶的合成及对糖基检测方法的构建
AU2017238392A1 (en) 2016-03-23 2018-09-27 Fimbrion Therapeutics, Inc. Mannose-derived antagonists of FimH useful for treating disease
KR102373502B1 (ko) * 2018-05-14 2022-03-11 주식회사 금호에이치티 골수유래억제세포 관련 질환의 예방 및 치료 용도
RS63712B1 (sr) 2018-07-10 2022-11-30 Glaxosmithkline Ip Dev Ltd Jedinjenja c-manozida korisna za tretman infekcija urinarnog trakta
CA3138394A1 (en) 2019-05-07 2020-11-12 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2020254369A1 (en) 2019-06-19 2020-12-24 Glaxosmithkline Intellectual Property Development Limited Substituted biphenyl or phenylheteroaryl-mannosides as antagonists of fimh
EP3757572A1 (de) * 2019-06-27 2020-12-30 Centre National de la Recherche Scientifique Nachweis von pathogenen bakterien durch chemisch funktionalisierte cellulose

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
JP3342749B2 (ja) * 1993-09-20 2002-11-11 積水化学工業株式会社 糖化蛋白の測定方法
EP0747705A1 (de) * 1995-06-09 1996-12-11 Bayer Corporation Spezifische Bestimmung von NCA 90 Glykoprotein im Blut eines Krebspatienten
CA2238262A1 (en) * 1995-11-22 1997-05-29 The Research And Development Institute, Inc. Therapeutic and diagnostic agents for the treatment of microbial infections
US5874233A (en) 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
US6290959B1 (en) * 1996-10-24 2001-09-18 New York University Method for screening compounds for inhibiting bacterial attachment to host cell receptors
NL1010770C2 (nl) * 1998-12-09 2000-06-13 Nutricia Nv Preparaat dat oligosacchariden en probiotica bevat.
US6942981B1 (en) * 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US7138237B1 (en) * 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
EP1381688A1 (de) * 2001-04-25 2004-01-21 N.V. Nutricia Verfahren zur fermentativen herstellung eines gesundheitsfördernden produktes
JP4947851B2 (ja) * 2001-06-07 2012-06-06 信紘 佐藤 潰瘍性大腸炎治療薬
AU2002313458A1 (en) * 2001-06-29 2003-03-03 Astion Development A/S Niaciamide and derivatives in combination with aminosugar
AU2002367696A1 (en) * 2001-10-12 2003-09-09 Mcgill University Enhanced immunization and suppression of oral tolerance
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
EP1651259A4 (de) * 2003-07-31 2008-05-28 Endacea Inc Verfahren und zusammensetzungen zur erzeugung von antigenen antworten
US7799328B2 (en) * 2004-12-23 2010-09-21 Biocodex Method for treating weight loss in patients suffering from inflammatory bowel diseases
KR101654537B1 (ko) * 2007-12-26 2016-09-06 르샤프르 에 꽁빠니 인간 및/또는 동물 영양을 위한 조성물, 이의 용도 및 효모균

Also Published As

Publication number Publication date
CA2582228C (fr) 2018-07-31
EP1800134B1 (de) 2008-11-26
US9176131B2 (en) 2015-11-03
WO2006040481A2 (fr) 2006-04-20
CA2582228A1 (fr) 2006-04-20
WO2006040481A3 (fr) 2006-08-31
EP1800134A2 (de) 2007-06-27
US20160091501A1 (en) 2016-03-31
DE602005011316D1 (de) 2009-01-08
JP2008517261A (ja) 2008-05-22
ES2317327T3 (es) 2009-04-16
JP4896883B2 (ja) 2012-03-14
US20100015600A1 (en) 2010-01-21
DK1800134T3 (da) 2009-03-16
FR2876798A1 (fr) 2006-04-21

Similar Documents

Publication Publication Date Title
Perneczky et al. Impairment of activities of daily living requiring memory or complex reasoning as part of the MCI syndrome
CY1125258T1 (el) Νεοι παραγοντες απεικονισης για ανιχνευση νευρολογικης δυσλειτουργιας
ATE415632T1 (de) Verfahren zur diagnose und behandlung von morbus crohn
DK1811303T3 (da) Forbindelser til behandling af irriteret tyktarm (IBS)
WO2007086986A3 (en) Novel application of biosensors for diagnosis and treatment of disease
EP1578371A4 (de) Zusammensetzungen und verfahren für die tumor-diagnose und behandlung
ATE440536T1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
WO2008134569A3 (en) Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
DE60325617D1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
EP1572091A4 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
WO2007123723A3 (en) Diagnosis and treatment of alzheimer's disease
WO2007011834A3 (en) Compounds and method for the diagnosis and treatment of amyloid associated diseases
DK1075277T4 (da) Fremgangsmåder til detektion og inhibering af angiogenese
ATE451477T1 (de) Diagnose und überwachung von hepatozellulärem karzinom
WO2004021008A3 (en) Methods for detecting breast and ovarian cancer
EP1742654A4 (de) Anti-lfl2-antikörper zur diagnose, prognose und behandlung von krebs
ATE514948T1 (de) In vitro verfahren zur diagnose von neurodegenerativen erkrankungen
ATE530667T1 (de) Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit
ATE546547T1 (de) Diagnose der chronischen abstossung
DE502006008028D1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
MX2021013715A (es) ENSAYO MULTIPLEX PARA DETERMINAR LA PROPORCION DE ß-AMILOIDE 42/40 EN MUESTRAS DE PLASMA HUMANO.
ATE495269T1 (de) Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen
BR0317404A (pt) Variantes do fator xiia
WO2006099569A3 (en) Methods and compositions for beryllium-induced disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties